Begin main content

Call for Patient Input: doravirine/lamuvidine/tenofovir disoproxil fumarate

Published on: September 14, 2018
Result type: News

CADTH has received the following drug submission(s) and/or notice(s) of pending submission(s). If you are interested in providing patient input, please click on “Submit.” For information about the patient input process or for additional instructions, please see the Patient Input page of our website.

doravirine/lamuvidine/tenofovir disoproxil fumarate

Brand name Generic name Manufacturer Indication(s)
TBD doravirine lamuvidine tenofovir disoproxil fumarate Merck Canada Inc. HIV-1
Project Number Call for patient input Patient input deadline Submit patient input
SR0581-000 2018-09-14 2018-11-05 Submit